Drugs / Histograft
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06365307 | Nov 2023 → Sep 2024 | cervical disk degenerative disorder, spinal stenosis | Histograft Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Histograft | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06365307 ↗ |
| Known as | Nucleostim-VEGF | “Osteoplastic material based on octacalcium phosphate and biologically active nucleic acids for bone tissue regeneration Nucleostim-VEGF ("Histograft")” NCT06365307 ↗ |
| Modality | Other / unclassified | “a bone substitute based on octacalcium phosphate (OCP) and plasmid DNA encoding VEGFA gene” NCT06365307 ↗ |
| Target | VEGFA | “plasmid DNA encoding VEGFA gene” NCT06365307 ↗ |